Sun Pharmaceutical Industries Ltd 2021 AR2
The report highlights Sun Pharma's performance during the fiscal year 2020-21, emphasizing its resilience and response to the COVID-19 pandemic. The company achieved a 2.5% growth in overall revenues, reaching INR 331 billion, driven by strong performance in its chronic segments in India and a ramp-up in global specialty sales. Sun Pharma expanded its field force in India to over 10,900 representatives and launched 96 new products. On the sustainability front, the company invested INR 269.5 million in CSR projects, focusing on healthcare, education, and COVID-19 relief, while generating 36.5 million kWh of clean energy.
Company: Sun Pharmaceutical Industries Ltd
Sector: Manufacturing
Country: India
Year: 2021
Type: AR2
Pages: 296
Back to company
Sun Pharmaceutical Industries Ltd
Annual Report
The report highlights Sun Pharma's performance during the fiscal year 2020-21, emphasizing its resilience and response to the COVID-19 pandemic. The company achieved a 2.5% growth in overall revenues, reaching INR 331 billion, driven by strong performance in its chronic segments in India and a ramp-up in global specialty sales. Sun Pharma expanded its field force in India to over 10,900 representatives and launched 96 new products. On the sustainability front, the company invested INR 269.5 million in CSR projects, focusing on healthcare, education, and COVID-19 relief, while generating 36.5 million kWh of clean energy.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Employees